Revealing the true targets for next generation immunotherapies We believe better cancer therapies are needed to transform people’s lives. We […]
Location: United Kingdom, England, South Hams
Employees: 1-10
Total raised: $45.65M
Investors 2
| Date | Name | Website |
| 02.05.2022 | Advent Lif... | adventls.c... |
| 18.05.2023 | Cambridge ... | cic.vc |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.10.2024 | Seed | $31M | - |
| 12.09.2024 | Grant | $652.27K | - |
| 26.04.2022 | Seed | $14M | - |
Mentions in press and media 10
| Date | Title | Description |
| 19.02.2025 | Epitopea announces license and research collaboration agreement with MSD to identify cryptigenTM tumor-specific antigens | Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, announces a license and research collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J.,... |
| 24.10.2024 | Epitopea Closes USD $31M Pre-Series A Financing | Epitopea, a Cambridge, UK- and Montreal, Canada-based cancer immunotherapeutics company, raised USD $31M in Pre-Series A funding. Backers included Investissement Québec, adMare BioInnovations, Jonathan Milner, existing investors Advent Life... |
| 12.09.2024 | Epitopea Receives £500K Grant from Innovate UK | Epitopea, a Cambridge, UK- and Montreal, Canada-based transatlantic cancer immunotherapeutics company, received a £500K Grant from Innovate UK. The company was selected to receive funding from Innovate UK’s Cancer Therapeutics programme, wh... |
| 26.04.2022 | CIC participates in Epitopea’s $13.6 million seed round on its mission to transform cancer therapeutics | Cambridge Innovation Capital participates in Epitopea’s $13.6 million seed round on its mission to transform cancer therapeutics Funding will support Novel Cryptigen™ technology unlocking full potential of Tumour Specific Antigens Cambridge... |
| 26.04.2022 | Epitopea prescribed £10m in funding for cancer research tech | Medech startup Epitopea has raised $13.6m (£10.3m) in seed funding from a transatlantic syndicate including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital (CIC) and Fonds de solidarité FTQ. Epitopea will use the seed ... |
| 25.04.2022 | Advancing cancer treatments, medtech startup Epitopea raises £10.3 million | Cambridge-based Epitopea has raised £10.3 million in a seed funding round. The medtech startup is developing off-the-shelf cancer immunotherapies designed to treat a broad patient population. The influx of capital will be used to further ad... |
| 25.04.2022 | Epitopea Raises $13.6M in Seed Funding | Epitopea, a Cambridge, UK- and Montreal, Canada-based transatlantic cancer immunotherapeutics company exploiting a new class of untapped tumour-specific antigens (TSAs), raised $13.6M (£10.3M) in seed funding. Backers included Advent Life S... |
| 25.04.2022 | Epitopea announces $14 Million financing to advance cancer immunotherapeutics | Epitopea announces $14 Million financing to advance cancer immunotherapeutics Novel CryptigenTM technology unlocks full potential of Tumour Specific Antigens Epitopea, a transatlantic cancer immunotherapeutics company and global leader in e... |
| - | Advancing cancer treatments, medtech startup Epitopea raises £10.3 million | Cambridge-based Epitopea has raised £10.3 million in a seed funding round. The medtech startup is developing off-the-shelf cancer immunotherapies designed to treat a broad patient population. The influx of capital will be used to further ad... |
| - | Epitopea | “Revealing the true targets for next generation immunotherapies We believe better cancer therapies are needed to transform people’s lives. We […]” |